News & Events zu Grifols SA (GRFS)GRFSGrifols SA

Grifols Completes Clinical Trial of SPARTA

Grifols announced the completion of the clinical portion of SPARTA, its phase 3 outcomes study evaluating the clinical efficacy and safety of two dose regimens of Prolastin-C in patients with emphysema associated with alpha-1 antitrypsin deficiency, also known as alpha-1. The last patient in the trial completed their final study visit last week. This milestone, known as "last patient, last visit" signifies completion of follow-up for all 345 enrolled participants. Topline results are expected by the end of this year.

Grifols Confirms No Change to EXCELL Phase III Trial Timeline

Grifols issued the following statement on the EXCELL Phase 3 trial timeline: "We have noted the recent Bloomberg article referring to the EXCELL Phase III trial timeline on ClinicalTrials.gov. The timeline currently reflected on the website is consistent with what was presented at our Capital Markets Day in February 2025, where completion was already envisaged in 2029. As such, this does not represent a new development or a delay to previously communicated guidance. Please find attached slide 91 attached below from our Capital Markets Day presentation. The full presentation is also available on our website."

Grifols Begins Two Phase 3 Trials

Grifols announced that the first patients have been dosed in two separate Phase 3 trials aiming to expand the U.S. labels for its signature immunoglobulin therapeutics, Gamunex-C, an intravenous immunoglobulin, and Xembify, its subcutaneous immunoglobulin.